Cyxone’s interim report for January-June 2018
Summary of interim reportFirst Half-year (1 January to 30 June 2018) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -6 503 (-4 075) · Earnings per share -0,37 (-0,27) · Cash and cash equivalents as of 30 June KSEK 17 817 (28 114) · Equity ratio as of 30 June 92,8 (95,2) % Second Quarter (1 April to 30 June 2018) · Operating revenue KSEK 0 (0) · Income after financial items KSEK -3 755 (-2 588) · Earnings per share -0,21 (-0,17) Significant events during the second quarter of 2018 · The company completed the acquisition of drug